Clinical Trials Browser

dacomitinib × CNS × Clear all

NCT01520870 2021-07-06

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Phase 2 Completed

49 enrolled 9 charts

Brain Neoplasms, Glioblastoma, Recurrence

NCT04675008 2021-01-05

Central Nervous System(CNS) Efficacy of Dacomitinib

Phase 2 Unknown

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT01112527 2018-08-16

PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma

Phase 2 Completed

Glioblastoma

NCT02047747 2016-09-22

A Phase II Study of Dacomitinib in Progressive Brain Metastases

Phase 2 Terminated

4 enrolled 4 charts

Brain Neoplasms, Neoplasm Metastasis